ICD-11Codes: 8A40.0
Conditions
Interventions
Group 1: Patients with neuroimmunological disease and healthy control participants are annually visited over a period of 15 years and characterized by a multimodal diagnostic panel and patient questio
other functional and cognitive assessments: Timed-25 Food Walk Test (T25-FW), Multiple Sclerosis Functional Composite (MSFC), Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS),
tests of the visual system: keratotonometrie, high and low contrast visual acuity, refraction, perimetrie, optical coherence tomography, uni and multifokal visual evoked potentials (VEP)
cerebrospinal magnet-resonance imaging (MRI)
questionnnaires regrading spasticity (MS-spasticity and related symptoms), all-day activities (GLTE-Q), self-assessment of impairment (PDDS), fatigue (FSS, FSMC), pain (BPI, PDQ), walking abilities (W
Sponsors
Charité - Universitätsmedizin Berlin, Experimental and Clinical Research Center (ECRC) AG Klinische Neuroimmunologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. MS diagnosis according to current diagnostic criteria (McDonald 2017) or NMOSD or MOGAD diagnosis according to current diagnostic criteria (Wingerchuck 2015) or other autoimmune disease affecting the central nervous system (e.g. radiographic isolated syndrome [RIS], isolated or recurrent optic neuritis, isolated myelitis, autoimmune glial fibrillary acidic protein [GFAP] encephalitis, autoimmune encephalitis, susac-syndrome, Balo's concentric sclerosis) or a self-reported healthy participant. 2. 18 years of age or older 3. able to give written informed consent. 4. proband has health insurance. 5. written consent was given.
Exclusion criteria
Exclusion criteria: 1. contraindication for magnet resonance tomography imaging 2. self-reported pregnancy 3. relevant other disease, which hinders the conduct of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The goal is a comprehensive multimodal characterization of different neuroimmunological disease entities to facilitate diagnostic differentiation between diseases and to identify predictors for the disease course. | — |
Secondary
| Measure | Time frame |
|---|---|
| structural, functional and patient reported outcome measures | — |
Countries
Germany
Contacts
Public ContactTanja Schmitz-Hübsch
Charité - Universitätsmedizin Berlin, Experimental and Clinical Research Center (ECRC), AG Klinische Neuroimmunologie, Studienambulanz am NeuroCure Clinical Reserach Center (NCRC)
Outcome results
None listed